Spots Global Cancer Trial Database for Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome

Official Title:

Study ID: NCT00004832

Conditions

Lambert-Eaton Myasthenic Syndrome

Interventions

3,4-diaminopyridine

Study Description

Brief Summary: OBJECTIVES: I. Evaluate the safety and effectiveness of 3,4-diaminopyridine (DAP) in the treatment of patients with Lambert-Eaton myasthenic syndrome (LEMS). II. Determine the side-effects and benefits associated with DAP.

Detailed Description: PROTOCOL OUTLINE: This is a randomized, double blind, placebo controlled study. Patients are randomized to receive 3,4-diaminopyridine (DAP) or placebo orally 3 times daily for 5 days, after which treatment is discontinued and patients are observed for at least 24 hours. At the end of the blinded study, patients may then elect to take open label DAP orally 3 times daily for 6 months; those who do so are monitored for clinical effects and side effects for at least 6 months.